BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI
admin By Colin Kellaher Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the…
Read MoreAlzheimers
Biogen shares jump 4.7% premarket on hopes for its Alzheimer’s treatment lecanemab
Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner…
Read MoreRoche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of…
Read MoreWhen will we care as much about Alzheimer’s as we did about COVID-19?
Where is the hysteria? Where is the mass panic? Where is the preening virtue signaling?…
Read More4 things you can do to fight dementia and improve your memory
There may not be a “magic pill,” but there are ways to stave off dementia…
Read MoreBiogen and Eisai make plans to take another Alzheimer’s drug to the FDA
Biogen Inc. BIIB, -1.93% and Eisai Co. Ltd. 4523, +3.57% are getting closer to a…
Read MorePeople who do this one thing have HALF the Alzheimer’s risk
The things to remember about dementia are that it is absolutely horrible for you and…
Read MoreGetting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive…
Read MoreRegulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read More
Want to slow, delay or reverse dementia? Try this classic game.
A couple of years ago I bought a big book of crosswords and started doing…
Read More